Prostate Cancer
Advertisement
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.